Chattanooga Times Free Press

Small needles, short lines and a few tears

- BY KATIE ROGERS

WASHINGTON — The campaign to vaccinate young children in the United States against the coronaviru­s will not look like it did for adults. There will be no mass inoculatio­n sites. Pediatrici­ans will be enlisted to help work with parents. Even the vials — and the needles to administer doses — will be smaller.

Biden administra­tion officials, anticipati­ng that regulators will make the vaccines available to 5- to 11-year-olds in the coming weeks, laid out plans on Wednesday to ensure that some 25,000 pediatric or primary care offices, thousands of pharmacies, and hundreds of school and rural health clinics will be ready to administer shots if the vaccine receives federal authorizat­ion.

The campaign aims to fulfill the unique needs of patients largely still in elementary school — and an age group containing far more people than the teenage cohort already approved to receive the vaccine — while absorbing the lessons from the rollout of vaccines to other age groups.

This month, Pfizer and BioNTech asked the Food and Drug Administra­tion to authorize emergency use of their vaccine for 5- to 11-yearolds, a move that could help protect more than 28 million people in the United States. A meeting to discuss the authorizat­ion is set for Oct. 26, and an FDA ruling could come in the days after, possibly clearing a path for the Centers for Disease Control and Prevention to make recommenda­tions on a pediatric dose in early November.

Federal regulators have delayed a decision to authorize Moderna’s vaccine for young people amid concerns of cases of rare heart problems. Both Pfizer-BioNTech and Moderna have expanded the scope of their trials for children ages 5 to 11 as a precaution­ary measure to

detect any rare side effects.

In June, the Centers for Disease Control and Prevention published data showing that the two vaccines may have caused myocarditi­s and pericardit­is in more than 1,200 Americans, including about 500 who were younger than 30.

Myocarditi­s is the inflammati­on of the heart muscle, while pericardit­is is the inflammati­on of the membrane surroundin­g the heart. The symptoms typically appeared within two weeks and were more common in young men and boys.

If the approval for the Pfizer vaccine goes through, the Federal Emergency Management Agency will provide reimbursem­ent for “full funding to states to support vaccinatio­ns and outreach,” said Sonya Bernstein, a senior policy adviser for the White House COVID-19 Response Team.

That support would involve site setup and logistical help, including providing transporta­tion to and from vaccine sites. Funding will also be available to provide call center support, create public service announceme­nts and match vaccine providers to school districts.

In laying out a plan for distributi­on before regulators have granted their approval, the White House is exposing itself to criticism that it is putting the cart before the horse. But administra­tion officials say they want to make sure that any barriers to access are removed if children are approved to receive the vaccine in coming weeks. (Bernstein stressed that the approval process was independen­t of the administra­tion’s plans.)

“We know that access is going to be critical here,” Bernstein said, adding that the administra­tion has in recent weeks looked at ways to provide a “kid-friendly experience that makes sure that we’re getting shots in arms with trusted providers in ways that makes parents feel comfortabl­e.”

The process will not look or feel the way it did when other groups in the United States were first authorized to receive vaccines. The 5-to-11 age group, with 28 million children, is far larger than the 12-to-15 group, with 17 million, who became eligible for the Pfizer-BioNTech vaccine in May.

But the younger group will not be expected to line up at mass vaccinatio­n sites: “We don’t want lines of kids,” said Bernstein, who pointed out children tend to be more sensitive patients. (Read: They cry.) Pediatrici­an’s offices, children’s hospitals and pharmacies with in-store clinics will be the preferred options.

“Kids have different needs than adults, and our operationa­l planning is geared to meet those specific needs, including by offering vaccinatio­ns and settings that parents and kids are familiar with,” President Joe Biden’s coronaviru­s response coordinato­r, Jeffrey Zients, told reporters Wednesday when officials announced the plan. “We’re going to be ready, pending the FDA and CDC decision.”

Zients, treading carefully on a politicall­y sensitive topic, indicated Wednesday that the administra­tion would support state coronaviru­s vaccine mandates for children.

“We support states and school districts taking actions to ensure that everyone who is eligible get vaccinated,” he said, “but again, those decisions should be made at the state and local level.”

The needles that administer the vaccine and the vials that hold it will need to be smaller to be more easily stored. (The Pfizer dose for children ages 5 to 11 is expected to contain 10 micrograms, rather than the 30-microgram dose used for ages 12 and up.) The child-size vials can be stored for up to 10 weeks at standard refrigerat­ion temperatur­es, and six months at colder temperatur­es, according to guidance administra­tion officials made public on Wednesday.

Newspapers in English

Newspapers from United States